NERV Minerva Neurosciences Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: NERV

Price (delayed)

$2.35

Market cap

$16.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$4.48

Enterprise value

-$18.48M

Minerva's portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease.

Highlights
The EPS is up by 18% year-on-year and by 2.8% since the previous quarter
Minerva Neurosciences's equity has decreased by 37% YoY and by 29% QoQ
The company's quick ratio fell by 14% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.minervaneurosciences.com
Peers: INCY DVAX MYGN

Key stats

What are the main financial stats of NERV
Market
Shares outstanding
6.99M
Market cap
$16.43M
Enterprise value
-$18.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$31.6M
EBITDA
-$31.57M
Free cash flow
-$20.76M
Per share
EPS
-$4.48
Free cash flow per share
-$2.74
Book value per share
-$5.23
Revenue per share
$0
TBVPS
$4.71
Balance sheet
Total assets
$50.51M
Total liabilities
$87.1M
Debt
$0
Equity
-$36.59M
Working capital
$32.79M
Liquidity
Debt to equity
0
Current ratio
12.58
Quick ratio
12.34
Net debt/EBITDA
1.11
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-53.2%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-66.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NERV stock price

How has the Minerva Neurosciences stock price performed over time
Intraday
0.86%
1 week
-3.29%
1 month
-6.56%
1 year
-48.8%
YTD
-61.79%
QTD
-8.91%

Financial performance

How have Minerva Neurosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$24.45M
Net income
-$31.6M
Gross margin
N/A
Net margin
N/A
The company's net income fell by 8% YoY and by 5% QoQ
NERV's operating income is down by 8% year-on-year and by 6% since the previous quarter

Growth

What is Minerva Neurosciences's growth rate over time

Valuation

What is Minerva Neurosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 18% year-on-year and by 2.8% since the previous quarter
Minerva Neurosciences's equity has decreased by 37% YoY and by 29% QoQ

Efficiency

How efficient is Minerva Neurosciences business performance
Minerva Neurosciences's return on assets has decreased by 6% QoQ and by 4.9% YoY

Dividends

What is NERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NERV.

Financial health

How did Minerva Neurosciences financials performed over time
The total assets is 42% less than the total liabilities
The company's quick ratio fell by 14% YoY
Minerva Neurosciences's current ratio has decreased by 14% YoY
The debt is 100% more than the equity
Minerva Neurosciences's equity has decreased by 37% YoY and by 29% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.